d-MAPPS™ for Graft-versus-Host Disease

This trial tests a new eye drop, d-MAPPS™ Ophthalmic Solution, to determine its effectiveness for individuals with chronic ocular graft-versus-host disease (oGVHD), a condition affecting the eyes after a stem cell transplant. The trial aims to assess the safety and effectiveness of these eye drops in reducing symptoms like dry eyes and discomfort. Participants will receive either the active treatment or a placebo for comparison. Suitable candidates for the trial are adults experiencing oGVHD after a stem cell transplant, with noticeable eye issues impacting their daily life. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to a potentially groundbreaking treatment.

Research has shown that d-MAPPS™ Eye Drops are generally safe and well-tolerated. Earlier studies found that people using eye drops similar to d-MAPPS™ experienced few side effects, mostly mild ones like temporary eye irritation, with no serious problems linked to the treatment. This suggests the treatment is safe for humans. As this trial is in a later stage, more evidence supports its safety.¹²³⁴⁵

Unlike standard treatments for Graft-versus-Host Disease, which often involve systemic immunosuppressive drugs, d-MAPPS™ Ophthalmic Solution targets the condition locally in the eyes. This precise application could potentially reduce the systemic side effects associated with broader treatments. Researchers are excited about this treatment because it uses a unique mechanism that directly addresses eye symptoms, offering hope for faster relief and improved quality of life for patients with ocular complications.

Research has shown that d-MAPPS™ Eye Drops may help treat chronic eye problems caused by ocular graft-versus-host disease (oGVHD). Studies have found that this treatment can relieve symptoms like dryness and irritation. In this trial, participants who received the active study drug, d-MAPPS™, experienced significantly better relief from these symptoms compared to those using a placebo. This suggests that d-MAPPS™ could be an effective option for managing oGVHD symptoms.¹²³⁴⁵